Open company graph database — free web & API
Login

Fuji Pharmaceutical Co., Ltd.

株式会社富士薬品
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
21,056
Related companies
30
§01

Basic information

BASIC
Head office
4-383 Sakuragi-cho, Omiya-ku, Saitama City, Saitama Prefecture, 330-9508, Japan
Chief executive
Masayuki Takayanagi
Capital
100,000,000
Employees (non-consolidated)
Employees (consolidated)
21,056 people
Start date
1954-04-01
End date
§02

Websites

2 DOMAINS
§03

Business

4
Prescription Drug Sales BusinessDrugstore and Pharmacy BusinessMedical Pharmaceutical Sales BusinessPharmaceutical Manufacturing Business
§04

Related companies

30 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Panakeia Pharmaceutical Co., Ltd.
Group
Moriki Co., Ltd.
Group
Hirosawa Pharmaceutical Sales Co., Ltd.
Group
Ost Japan Group Co., Ltd.
Group
Tokai Seims Co., Ltd.
Group
Satomi Fuji Pharmacy LLC
Group
Miura Fuji Pharmaceutical Co., Ltd.
Group
Nakao Fuji Pharmaceutical Co., Ltd.
Group
Nakatatsu Fuji Pharmaceutical Co., Ltd.
Group
Katsushita Fuji Pharmaceutical Co., Ltd.
Group
Komatsu Fuji Pharmaceutical Co., Ltd.
Group
Kishimoto Fuji Pharmaceutical Co., Ltd.
Group
Jinbo Fuji Pharmaceutical Co., Ltd.
Group
JC Pharmaceutical Sales Co., Ltd.
Group
Amihama Pharmacy Co., Ltd.
Group
Cosmo Pharmaceutical Co., Ltd.
Group
Chiba Fuji Pharmaceutical Co., Ltd.
Group
Fuji Pharmaceutical Solutions Co., Ltd.
Group
West Japan Seims Co., Ltd.
Group
Yutaka Pharmacy Co., Ltd.
Group
Towa Pharmaceutical Co., Ltd.
Group
Kyushu Seims Co., Ltd.
Group
株式会社共栄薬品販売
Group
株式会社内山薬品商会
Group
株式会社富士薬品ユニバーサルネット
Group Subsidiary
株式会社富士薬品販売
Group
株式会社新生オリエックス社
Group
有限会社中山富士薬品
Sato Fuji Pharmaceutical Co., Ltd.
Furuichi Fuji Pharmaceutical Co., Ltd.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

175 EVENTS

Commenced prescription drug sales business in Toyama City, Toyama Prefecture.Sources

Established Takayanagi Pharmaceutical Trading Company, Ltd.Sources

Established a new branch office in Maebashi City, Gunma Prefecture.Sources

Renamed to Fuji Pharmaceutical Ltd.Sources

Converted to a corporation.Sources

Established a branch office in Hino City, Tokyo to expand distribution channels for prescription drug sales business.Sources

Expanded into the southern Kanto region.Sources

Expanded into the Hokuriku region.Sources

Expanded into the northern Kyushu region.Sources

Expanded into the Tokai region.Sources

Expanded into the Tohoku region.Sources

Expanded into the Hokkaido region.Sources

Expanded into the Kinki region.Sources

Expanded into the Chubu region.Sources

Moved headquarters to the current location (4-383 Sakuragi-cho, Omiya-ku, Saitama City, Saitama Prefecture, 330-9508, Japan).Sources

Expanded into the Shikoku region.Sources

Started establishing a regional sales subsidiary.Sources

Expanded into the Southern Kyushu region.Sources

Constructed the Toyama factory in Fuchu Town, Fuku District, Toyama Prefecture (now Fuchu Town, Toyama City).Sources

Commenced in-house production of the comprehensive gastrointestinal medicine 'Fuji GI Medicine'.Sources

Commenced in-house production of the antipyretic analgesic 'New Kaiteki Z'.Sources

Commenced in-house production of the comprehensive cold medicine 'Shin Jikina Granules'.Sources

Established the Fuji Training Center in Fuchu Town, Fuku District, Toyama Prefecture (now Fuchu Town, Toyama City).Sources

Expanded the Toyama factory and began in-house production of drink, eye drop, and ointment preparations.Sources

Established a pharmaceutical research and development division and set up the First Research Institute in Ōmiya City, Saitama Prefecture (now Saitama City).Sources

Constructed the Toyama Second Factory adjacent to the Toyama factory.Sources

Commenced the drugstore business.Sources

Absorbed and merged with Okayama Fuji Pharmaceutical Co., Ltd. and Yamaguchi Fuji Pharmaceutical Co., Ltd.Sources

Commenced manufacturing and sales of medical drugs.Sources

Established the Second Research Institute in Ōmiya City, Saitama Prefecture (now Saitama City) for pharmacological research.Sources

Absorbed and merged with Miyazaki Fuji Pharmaceutical Co., Ltd. and Tosu Fuji Pharmaceutical Co., Ltd.Sources

Absorbed and merged with Tōura Fuji Pharmaceutical Co., Ltd.Sources

Established an automatic rack-type warehouse at the Toyama factory.Sources

Increased capital to 315,459,950 yen through a third-party allotment of capital increase.Sources

Participated in the management of Ooata Drug Co., Ltd.Sources

Established Cosmo Pharmaceutical Co., Ltd.Sources

Expansion of the Toyama factorySources

Completion of the New Second Research InstituteSources

Absorption merger of Ueda Fuji Pharmaceutical Co., Ltd. and Hidaka Fuji Pharmaceutical Co., Ltd.Sources

Acquisition of all shares of Towa Pharmaceutical Co., Ltd.Sources

Capital participation in Abeer Co., Ltd.Sources

Completion of the head office annexSources

Capital participation in G.C.C. Ltd.Sources

Establishment of Ohashi Emergency Pharmaceutical Co., Ltd.Sources

Top partner agreement with Omiya Ardija, a club in the Japan Professional Soccer League.Sources

Formation of Fuji Pharmaceutical UnionSources

Capital participation in Rise Co., Ltd.Sources

Capital participation in Sante Drug Co., Ltd. (formerly Yoshikawa Sante)Sources

Acquisition of all shares of Panakeia Pharmaceutical Co., Ltd. (formerly Takao Nakagaku Pharmaceutical)Sources

Joint establishment of Fine Pharmaceutical Co., Ltd.Sources

Acquisition of all shares of Lion Create Co., Ltd.Sources

Capital participation in Kyowa Trading Co., Ltd.Sources

Capital participation in Moriki Co., Ltd.Sources

Establishment of Fact Pharmaceutical Co., Ltd.Sources

Acquisition of the Shikoku regional sales rights from Drag Lion Co., Ltd., and commencement of operations as the Shikoku Division.Sources

Acquisition of all shares of Sasao Pharmacy Co., Ltd.Sources

Capital participation in Lemon Co., Ltd.Sources

Established Lead Pharmaceutical Co., Ltd.Sources

Capital participation in Hoshino Co., Ltd.Sources

Acquired the Okayama region sales rights from Drag Lion Co., Ltd., and commenced operations as the Chūshikoku Business Division.Sources

Acquired all shares of Cosmos 21 Drug Store Co., Ltd.Sources

Acquired all shares of Kirin Drug Store Co., Ltd.Sources

Acquired the sales rights of Taiyo and commenced operations as Just Drug Co., Ltd.Sources

Acquired the sales rights of Inaba and transferred them to Moriki Co., Ltd.Sources

Acquired the sales rights of Orix and commenced operations as Shinsei Orix Co., Ltd.Sources

Acquired all shares of Moriyama Pharmacy Co., Ltd.Sources

Completion of expansion works at the Toyama Second Factory.Sources

Acquired all shares of Tamura Pharmacy Co., Ltd.Sources

Entered into a business partnership and capital participation with Yutaka Pharmacy Co., Ltd.Sources

Acquired all shares of Powers Drug Co., Ltd.Sources

Acquired all shares of Shinoda Pharmacy Co., Ltd.Sources

Absorbed and split the Chūshikoku Business Division, and renamed the company to Chūshikoku Seims Co., Ltd.Sources

Established Medical Cosmos Pharmaceutical Co., Ltd.Sources

Capital participation in Drag Ozone Co., Ltd.Sources

Completion of comprehensive renovation works at the Toyama Factory.Sources

Acquired all shares of Happy Door Co., Ltd.Sources

Acquisition of all businesses of Abeel Co., Ltd.Sources

Start of sales of the renal function test drug "InuRidge® Injection".Sources

Acquisition of all shares of TriX Co., Ltd.Sources

Obtained ISO 14001 certification for the Toyama factory.Sources

Established Shinkou Seikaku Pharmaceutical Co., Ltd.Sources

Acquisition of all shares of Myoujou Pharmaceutical Co., Ltd.Sources

Acquisition of all shares of Taiyodo Pharmaceutical Co., Ltd.Sources

Acquisition of all businesses of Happy Door Co., Ltd.Sources

Capital participation in Drugstore Baigo Co., Ltd.Sources

Acquisition of all shares of Alpha Co., Ltd.Sources

Acquisition of all businesses of Shinoda Pharmacy Co., Ltd.Sources

Capital participation in Shibata Pharmaceutical Co., Ltd.Sources

Established Boso Fuji Pharmaceutical Co., Ltd.Sources

Acquisition of all shares of Uchiyama Pharmaceutical Trading Co., Ltd.Sources

Established Shinpou Pharmaceutical Co., Ltd.Sources

Established New Saitama Pharmaceutical Co., Ltd.Sources

Established Fuji Pharmaceutical Universal Network (Special Subsidiary) Co., Ltd.Sources

Moriki Co., Ltd. absorbed Tamura Co., Ltd. and Powers Drug Co., Ltd.Sources

Acquisition of all shares of Kyousei Pharmaceutical Industry Co., Ltd.Sources

Established Shin Kyousei Pharmaceutical Co., Ltd.Sources

Opened the Omiya headquarters and consolidated corporate functions.Sources

Alpha Co., Ltd. acquired part of Lion Create Co., Ltd.'s business and changed its name to Tohoku Seims Co., Ltd.Sources

Chugoku Shikoku Seims Co., Ltd. absorbed Drugstore Cosmos 21 Co., Ltd. and changed its name to West Japan Seims Co., Ltd.Sources

Established Tokai Seims Co., Ltd.Sources

Just Drug Co., Ltd. absorbed Shibata Pharmaceutical Co., Ltd. and changed its name to Kanto Seims Co., Ltd.Sources

Acquired all shares of Nozaki Pharmaceutical Co., Ltd.Sources

Established a local subsidiary, Fukata Meiken Trading Co., Ltd., in Shanghai.Sources

Kyoei Pharmaceutical Industry Co., Ltd. absorbed Panakeia Pharmaceutical Co., Ltd. and changed its name to Panakeia Pharmaceutical Co., Ltd.Sources

Smile Drug Co., Ltd. absorbed YS Trading Co., Ltd.Sources

J.C. Co., Ltd., Taiyodo Pharmaceutical Co., Ltd., Cosmos Pharmaceutical Shingu Co., Ltd., and Shin Kō Seimei Pharmaceutical Co., Ltd. were absorbed.Sources

Fuso Fuji Pharmaceutical Co., Ltd. absorbed Chiba Fuji Pharmaceutical Co., Ltd. and changed its name to Chiba Fuji Pharmaceutical Co., Ltd.Sources

Noble Pharmaceutical Co., Ltd. changed its name to Neo Pharmaceutical Co., Ltd.Sources

New Saitama Pharmaceutical Co., Ltd. changed its name to Fuji Pharmaceutical Sales Co., Ltd.Sources

Opened the first Drug Seims (Imis) store in Shanghai.Sources

Invested capital in Samoa Bio Inc.Sources

Changed the shareholder register custodian to Mizuho Trust Bank.Sources

Entered a capital and business alliance with Ost Japan Group Co., Ltd.Sources

Absorbed Lion Create Co., Ltd.Sources

Absorbed Miyas Fuji Land and Building Co., Ltd. and Create Ltd.Sources

Signed a contract with male professional tennis player Uchiha Kaito.Sources

Obtained manufacturing and sales approval for the hyperuricemia treatment drug 'Topiric® tablets'.Sources

Commenced sales of the hyperuricemia treatment drug 'Topiric® tablets'.Sources

Absorbed and merged with Dragestore Baigo Co., Ltd.Sources

Acquired all shares of Kusuri no Tsurumido Co., Ltd.Sources

Acquired all shares of Yutaka Pharmacy Co., Ltd.Sources

Signed sponsorship agreements with professional female golfers Ayaka Watanabe and Mitsuri Fujita.Sources

Initiated long-term prescriptions for 'Topiric® tablets'.Sources

Absorbed and merged with Kanto Seims Co., Ltd.Sources

Signed a sponsorship agreement with professional female tennis player Kurumi Nara.Sources

Completion of the new factory of Panakeia Pharmaceutical Co., Ltd.Sources

Absorbed and merged with Tohoku Seims Co., Ltd. and S-Route Co., Ltd.Sources

Launched the support program for junior female tennis players, 'Fuji Pharmaceutical Seims World Challenge Program', and held the first 'Fuji Pharmaceutical Seims Girls Cup' to select participants.Sources

Acquired all shares of Kyūmeidō Co., Ltd.Sources

Nippon Seiei Co., Ltd. inherits and acquires the pharmacy dispensing business of a subsidiary of the Health Science Group Headquarters.Sources

Hosted the first edition of the International Tennis Federation-sanctioned tournament 'Fuji Pharmaceutical Seims Women's Cup'.Sources

Absorbed and merged with Kyushu Seims Co., Ltd. and Kyūmeidō Co., Ltd.Sources

Withdrawn from Shanghai.Sources

Applied for manufacturing and sales approval in Japan for the gout and hyperuricemia treatment drug 'FYU-981' (generic name: Doxinurad).Sources

Hosted the third ITF Circuit 'Fuji Pharmaceutical Seims Women's Cup' tournament.Sources

Liquidated Zhonghua Shengyi Technology Co., Ltd. (Samoa Bio Inc.).Sources

MoriKi Co., Ltd. absorbs and merges with Tohoku Seims Co., Ltd.Sources

Acquires all shares of Amiha Pharmacy Co., Ltd.Sources

Signs a contract with professional female tennis player Sato Kumanari.Sources

Signs a sponsorship contract with professional female golfer Haruka Morita.Sources

Accepts inspection at the Toyama Second Factory for obtaining FDA certification.Sources

Obtains manufacturing and sales approval in Japan for the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)'.Sources

Signs a license agreement for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in China.Sources

Absorbs and merges with Smile Drug Co., Ltd.Sources

Acquires all shares of Taiyo-do Co., Ltd.Sources

Establishes Tokyo headquarters in Chiyoda-ku, Tokyo, and relocates headquarters functions.Sources

Launches sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)'.Sources

Transfers part of the rights and obligations related to the insurance pharmacy business of Nohin Co., Ltd. to MoriKi Co., Ltd. through a corporate split.Sources

Transfers all rights and obligations except those transferred in the above corporate split, and absorbs and merges with Nohin Co., Ltd.Sources

Announces exclusive license agreement with Fortress Biotech, Inc. for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in North America and Europe.Sources

Seims signs a top partner agreement with Omiya Ardija Ventus, which entered the first Japanese women's professional soccer league 'WE League' in September 2021.Sources

Formulates the Fuji Pharmaceutical Group slogan.Sources

Signs a license agreement with Eisai for development and sales of the hyperuricemia treatment drug 'Yuris® tablets (generic name: Doxilurad)' in five ASEAN countries.Sources

Subsidiary Yutaka Pharmacy Co., Ltd. absorbs and merges with Taiyo-do Co., Ltd.Sources

Signs an exclusive license agreement with Shengda Chemical Pharmaceutical Co., Ltd. for development and sales of 'Yuris® tablets' in Taiwan.Sources

Certified as a 'White 500' health management excellence corporation.Sources

Signed a sponsorship contract with female professional golfer Ayako Yamada.Sources

Signed a comprehensive cooperation agreement on health promotion with Uonuma City, Niigata Prefecture, and began initiatives in collaboration with local governments starting with this.Sources

Received Silver certification for the PRIDE Index, an evaluation metric for LGBTQ+ and other sexual minorities.Sources

Expanded the territory covered by the exclusive license agreement with Fortress Biotech, Inc. for the development and sale of Yuris® tablets to include the Middle East and North Africa, including Turkey.Sources

Certified as a White 500 health management excellence corporation for the second consecutive year.Sources

Initiated health management support services for companies that contract placement drugs.Sources

Started handling disaster prevention supplies for companies that contract placement drugs.Sources

Introduced "Same Touch" in all Fuji Pharmacy Group drugstores except Drag Yutaka.Sources

Relocated the First Research Institute to Shonan Health Innovation Park (1-26-1 Murouka Higashi 2-chome, Fujisawa City, Kanagawa Prefecture).Sources

Received Gold certification for the PRIDE Index 2023, the highest evaluation for LGBTQ+ and other sexual minorities.Sources

In response to Kyoha Shoji Co., Ltd.'s share buyback, the company withdrew from the Fuji Pharmacy Group.Sources

Certified as a White 500 health management excellence corporation for the third consecutive year.Sources

Signed a membership contract with tennis player Sakura Saito.Sources

Relocated the Omiya headquarters to AddGrace Omiya (1-398-1 Sakuragicho, Omiya-ku, Saitama City, Saitama Prefecture).Sources

Made Rakuten Point Card available at Fuji Pharmacy Group drugstores such as "Seimus".Sources

Certified as "Kurumin Plus" by the Ministry of Health, Labour and Welfare.Sources

Obtained approval in Thailand for the gout and hyperuricemia drug "Dochinurad".Sources

Won Gold, the highest rating for two consecutive years, in the PRIDE Index 2024 for LGBTQ+ and other sexual minorities.Sources

Obtained approval in China for the gout indication associated with hyperuricemia for the gout and hyperuricemia drug "Dochinurad".Sources

§07

News

11 ARTICLES

Warm Herbal Ginger November 1 ReleaseSources

Fuji Pharmaceutical will launch the powdered beverage 'Warm Herbal Ginger' from the health food brand 'Delicharm' in a limited quantity on November 1, 2026. It is a yuzu-flavored product that combines ginger, Hihatsu, hesperidin, and rough chamomile, dissolved in hot water. In addition to prescription drug sales, it will be tested for sale in some Fuji Pharmaceutical Group drugstore locations.

Fuji Eye AL Premium new release November 1Sources

Fuji Pharmaceutical will launch the second-class drug 'Fuji Eye AL Premium' from the eye drop brand 'Fuji Eye' on November 1, 2026. It contains five active ingredients that suppress the release and action of histamine and soothe inflammation, providing effective relief from itchy eyes caused by pollen and house dust.

Fuji Pharmaceutical launches Winter Appreciation CampaignSources

From November 1, 2026 to December 31, 2026, Fuji Pharmaceutical will hold the "Winter Appreciation Campaign." Purchases of 2,000 yen or more including tax, with eligible products, can be entered via LINE. 570 lucky winners will receive a QUO Card Pay (up to 10,000 yen) usable at Fuji Pharmaceutical Group drugstores. Eligible products can be purchased at the group's drugstores, official online store, or in-store pharmacies.

Fuji Pharmaceutical to Relaunch Fuji's Green Juice as a Foods with Function Claims ProductSources

Fuji Pharmaceutical Co., Ltd. will relaunch Fuji's Green Juice, part of its Delicharm health food brand, as a Foods with Function Claims product on October 1, 2026. The green juice contains six ingredients, vitamins, and dietary fiber, and will be available through Fuji Pharmaceutical's sales channels.

Fuji Yakuhin to Launch New Laforth Functional Food “Kore脂 Down W”Sources

Fuji Yakuhin announced that it will launch Kore脂 Down W, a new food with functional claims under its Laforth supplement brand, on September 1, 2026. It is intended for people concerned about obesity, high BMI, or high LDL cholesterol.

Tsukai Enema for Constipation to Launch on August 1Sources

Fuji Yakuhin announced that its Tsukai® Enema line, for relief from difficult constipation, will launch on Saturday, August 1, 2026. It will be available in three sizes: 10 g, 30 g, and 40 g, at drugstores including SEIMS and through the official online store.

Fuji Time AQUA White Grape Mix to Launch in Limited QuantitiesSources

Fuji Yakuhin will release Fuji Time AQUA White Grape Mix, a limited-edition flavor of its apple vinegar drink in the Fuji Time line under the Delicharm health food brand, on Saturday, August 1. The product line has sold more than 10 million bottles. It is available through home-delivery medicine sales, drugstores, and Fuji Yakuhin’s official online store.

Fuji Arrow® A Cream for Adult Acne to Launch July 1Sources

Fuji Yakuhin Co., Ltd. will launch Fuji Arrow® A Cream, a topical medicine, on Wednesday, July 1, 2026. It contains antibacterial and anti-inflammatory ingredients to suppress bacteria that cause adult acne and reduce inflammation.

Fuji Arrow® DZ Cool Cream Launches July 1 to Relieve Itching in Sensitive AreasSources

Fuji Yakuhin Co., Ltd. will launch Fuji Arrow® DZ Cool Cream, a new product in its topical medicine line, on Wednesday, July 1, 2026. The cream contains diphenhydramine hydrochloride, lidocaine, and l-menthol to relieve itching in sensitive areas while providing a cooling sensation. It will be available at drugstores and through the official online store.

Fuji Yakuhin Named to White 500 for Fifth Consecutive YearSources

Fuji Yakuhin Co., Ltd. has been named to the White 500 list of Excellent Health Management Corporations for the fifth consecutive year and has received Excellent Health Management Corporation recognition for seven consecutive years. Across the group, 10 companies, including Fuji Yakuhin, were recognized as Excellent Health Management Corporations 2026.

§08

Public records

GOV
National Tax Agency basic information4030001007483
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社富士薬品
Trade name (kana)
フジヤクヒン
Name in English
Corporation type
301
Address
〒330-0854 埼玉県さいたま市大宮区桜木町4丁目383番地
Postal code
3300854
Prefecture code
11
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2021-04-21
Change date
2021-04-06
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
令和3年4月1日さいたま市大宮区桜木町四丁目383番地株式会社日栄(1030002010456)を合併
Latest record
1
Excluded from search
0
Processing type
71
Correction type
0
Trade name image ID
Address image ID
Sequence number
863736
METI gBizINFO4030001007483
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4030001007483
Trade name
株式会社富士薬品
Trade name (kana)
フジヤクヒン
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
埼玉県さいたま市大宮区桜木町4丁目383番地
Postal code
3300854
Prefecture
埼玉県
Prefecture code
11
City or district
さいたま市大宮区
City code
103
Street address
桜木町4丁目383番地
Organisation type
301
Processing type
71
Correction type
0
Status
Representative
Capital
Employees
11537
Employees (male)
5085
Employees (female)
6452
Business summary
医薬品等の配置薬販売事業、薬局販売等、製造
Website URL
http://www.fujiyakuhin.co.jp
Year founded
Business category
I:卸売業、小売業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2021-04-21
Key information
4030001007483
§09

Sources & updates

SOURCES
↑